Will Indians get blockbuster weight-loss drugs at cost of cheaper insulin?

Will Indians get blockbuster weight-loss drugs at cost of cheaper insulin?

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote its new, blockbuster drugs such as Ozempic and Wegovy. But why is the company making the move? Will Indians now lose access to cheaper insulin drugs?

Ozempic pens sit on a production line at Novo Nordisk’s site in Hillerod. Reuters